Pfizer Gets Boost From Eliquis and 2 Dow Movers Changing Hands

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Microsoft Corporation’s (NASDAQ:MSFT) board sees the Netflix (NASDAQ:NFLX) Chief Executive Reed Hastings ready to step down. Hastings has said that the crucial struggle facing Microsoft centers around Windows 8 along with the way in which they use the new operating system to compete with “a better set of competitors than they’ve ever had, in Google (NASDAQ:GOOG) and Apple (NASDAQ:AAPL),” says AllThingsD.

Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.

Pfizer (NYSE:PFE) and Bristol-Myers Squibb’s (NYSE:BMY) new blood thinner Eliquis has been okayed by European regulators to prevent stroke in patients suffering from atrial fibrillation, exposing the drug to a much bigger market. The new approval marks the drug’s first global clearance for that use and its first big step toward stardom. Millions of European patients have atrial fibrillation and studies have shown its prevalence is on the rise. Even though Eliquis only brought in $1 million for Bristol-Myers Squibb during the third quarter, its approval for clot prevention in certain surgery patients might significantly prompt the drug to fly in the AF market.

Verizon Communications (NYSE:VZ) has not officially released information, but its Verizon Galaxy S3 Android 4.1 launch might be a bit sooner than expected.

Don’t Miss: Wow: Frank Quattrone at the Center of This Incredible Controversy at Hewlett-Packard.


More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business